Juan M Funes
Overview
Explore the profile of Juan M Funes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez-Navarro E, Conteduca V, Funes J, Dominguez J, Martin-Serrano M, Cremaschi P, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061175
The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as transcriptional profiling and immune cell ratios. We aimed to address the contribution...
2.
Kalbasi A, Tariveranmoshabad M, Hakimi K, Kremer S, Campbell K, Funes J, et al.
Sci Transl Med
. 2020 Oct;
12(565).
PMID: 33055240
Defects in tumor-intrinsic interferon (IFN) signaling result in failure of immune checkpoint blockade (ICB) against cancer, but these tumors may still maintain sensitivity to T cell-based adoptive cell therapy (ACT)....
3.
Lord S, Funes J, Harris A, Quintela-Fandino M
Curr Drug Targets
. 2016 Mar;
17(15):1714-1727.
PMID: 26953245
Antiangiogenic resistance is a major problem in cancer therapeutics. Preclinical research has identified several compensatory proangiogenic pathways that arise upon vascular endothelial growth factor inhibition, several of which have led...
4.
Miranda A, Funes J, Sanchez N, Limia C, Mesa M, Quezada S, et al.
Cancer Res
. 2015 Jun;
75(15):3032-42.
PMID: 26069249
Immune escape is a hallmark of cancer, but whether it relies upon extrinsic immune-selective pressure or is inherently orchestrated by oncogenic pathways is unresolved. To address this question, we took...
5.
Sanchez N, Miranda A, Funes J, Hevia G, Perez R, Leon J
Cell Immunol
. 2014 May;
289(1-2):174-84.
PMID: 24841856
Stem cells from mesenchymal origin (MSC) exert a plethora of immunomodulatory effects. We created a neoplastic model based on in vitro step-wise transformation to assess whether oncogenic pathways have the...
6.
Funes J, Henderson S, Kaufman R, Flanagan J, Robson M, Pedley B, et al.
Mol Cancer
. 2014 Feb;
13:20.
PMID: 24491031
Background: The transcription factor Nrf2 is a key regulator of the cellular antioxidant response, and its activation by chemoprotective agents has been proposed as a potential strategy to prevent cancer....
7.
Rodriguez R, Tornin J, Suarez C, Astudillo A, Rubio R, Yauk C, et al.
Stem Cells
. 2013 Jul;
31(10):2061-72.
PMID: 23836491
Increasing evidence supports that mesenchymal stromal/stem cells (MSCs) may represent the target cell for sarcoma development. Although different sarcomas have been modeled in mice upon expression of fusion oncogenes in...
8.
Egbuniwe O, Idowu B, Funes J, Grant A, Renton T, Di Silvio L
Cell Cycle
. 2011 Nov;
10(22):3912-9.
PMID: 22067611
Introduction: Residing within human dental pulp are cells of an ectomesenchymal origin which have the potential to differentiate into odontoblast-like cells. These cells have a limited growth potential owing to...
9.
Yi J, Dhir M, Van Neste L, Downing S, Jeschke J, Glockner S, et al.
Clin Cancer Res
. 2011 Feb;
17(6):1535-45.
PMID: 21278247
Purpose: The importance of genetic and epigenetic alterations maybe in their aggregate role in altering core pathways in tumorigenesis. Experimental Design: Merging genome-wide genomic and epigenomic alterations, we identify key...
10.
Wild L, Funes J, Boshoff C, Flanagan J
Carcinogenesis
. 2010 May;
31(10):1854-62.
PMID: 20466760
Genome-wide DNA hypomethylation was one of the first epigenetic alterations described in cancer cells. However, the cause of this hypomethylation is still poorly understood. We have previously developed a line...